Cue Biopharma, Inc. (CUE) News
Filter CUE News Items
CUE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CUE News Highlights
- For CUE, its 30 day story count is now at 7.
- Over the past 28 days, the trend for CUE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- BODY, EYE and VIEW are the most mentioned tickers in articles about CUE.
Latest CUE News From Around the Web
Below are the latest news stories about CUE BIOPHARMA INC that investors may wish to consider to help them evaluate CUE as an investment opportunity.
Cue Biopharma to Present at the Jefferies 2023 Global Healthcare ConferenceBOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that it will present at the Jefferies Global Healthcare Conference being held June 7–9, 2023 in New York. The Company will provide a corporate update highlighting the most recent clinical progress for CUE-101, its lead |
3 Biotech Stocks Sitting on Huge-Upside CatalystsThe biotech boom is hot. |
Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingAs of the data cutoff date, nine of the 14 evaluable patients treated with CUE-101+ KEYTRUDA® (pembrolizumab) demonstrated tumor regression, with five confirmed partial responses (PRs) and three durable stable disease (DSD) responses, two of which have tumor burden reductions of -18% and -24% and remain on treatment100% of patients treated with CUE-101+ pembrolizumab at the recommended phase 2 dose (RP2D) of 4mg/kg (n=16) remain alive to date following treatment As of the data cutoff date, CUE-1 |
Cue Biopharma to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingCompany to host Investor Update call on June 14, 2023 to review and discuss the clinical progress and associated data presented at ASCO BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today the presentation of a poster at the American Society of Clinical Oncology (ASCO) Ann |
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue EstimatesCue Biopharma, Inc. (CUE) delivered earnings and revenue surprises of 12.12% and 37.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business HighlightsBOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, provided a business and financial update for the first quarter 2023. Recent Business Highlights CUE-101 abstract accepted for presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting scheduled for Ju |
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences ConferenceBOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held at the New York Hilton Midtown, May 15-16, 2023. During the fireside chat, Cue Biopharma will provide an update on ongoi |
7 Hot Growth Stocks Poised to Triple in 2023These hot growth stocks to buy can triple in price in 2023, with some holding impressive upside that's much higher. |
7 High-Potential Penny Stocks in the Biotech SectorMost of the biggest biotech stocks on the market started off as unknown penny stocks. |
Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of DirectorsBOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today the appointment of seasoned pharmaceutical executive Pamela D. Garzone, Ph.D., to its board of directors. Dr. Garzone brings to Cue Biopharma more than 25 years of healthcare and pharmaceutical industry experience in d |